inactivated trivalent influenza vaccine

The inactivated trivalent influenza vaccine (TIV) is a seasonal biologic vaccine designed to provide protection against three strains of the influenza virus, typically including two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage. The vaccine consists of inactivated (killed) virus particles, often in a split-virion or subunit formulation, which are unable to cause disease but stimulate the host immune system to produce neutralizing antibodies against surface glycoproteins, primarily hemagglutinin (HA) and neuraminidase (NA). By blocking these proteins, the vaccine prevents viral attachment to host cells and subsequent replication. TIV is traditionally administered via intramuscular injection and is updated annually to match circulating strains as recommended by the World Health Organization (WHO). In clinical studies, such as those conducted by Sanofi Pasteur and academic collaborators like Wayne Sullender, M.D., TIV has been shown to provide both direct protection to vaccinees and indirect (herd) protection to unvaccinated household members.

Brand names

VaxigripFluzoneFluarixFluviralAgrifluFluvirinMutagrip

Other names

Trivalent inactivated influenza vaccineSplit-virion influenza vaccineTrivalent seasonal influenza vaccine